

A2 1. (Amended) A pulmonary liquid or dry formulation comprising a GLP-1 compound [whereto is attached] wherein a lipophilic substituent is optionally attached via a spacer.

Claim 4, line 1, delete "any one of claims 1-3" and insert --claim 1--.

Claim 5, line 1, delete "any one of claims 1-4" and insert --claim 1--.

Claim 6, line 1, delete "any one of claims 1-5" and insert --claim 1 --.

A2 8. (Amended) The pulmonary formulation of claim 1 wherein said GLP-1 compound [whereto is attached] wherein a lipophilic substituent is attached via a spacer is Arg³⁴Lys²⁶(N^ε-(γ-glutamyl(N^α-hexadecanoyl))) -GLP-1(7-37)-OH, Arg¹⁸, Leu²⁰, Gln³⁴, Lys³³ (N^ε-(γ-aminobutyryl(N^α-hexadecanoyl))) Exendin-4-(7-45)-NH₂ or Arg³³, Leu²⁰, Gln³⁴, Lys¹⁸ (N^ε-(γ-aminobutyryl(N^α-hexadecanoyl))) Exendin-4-(7-45)-NH₂.

Claim 9, line 1, delete "anyone of claims 1-8" and insert --claim 1--.

10. (Amended) A pulmonary delivery device comprising a GLP-1 compound [whereto is attached] wherein a lipophilic substituent is optionally attached via a spacer.

11. (Amended) A method for preparing a pulmonary liquid or dry formulation for use in a pulmonary device, said formulation comprising a GLP-1 compound [whereto is attached] wherein a lipophilic substituent is optionally attached via a spacer.

A3 12. (Amended) A method for preparing a pulmonary delivery device, said device comprising a GLP-1 compound [whereto is attached] wherein a lipophilic substituent is optionally attached via a spacer.

13. (Amended) A method of reducing blood glucose levels, treating diabetes type I, diabetes type II, or obesity, or inhibiting gastric acid secretion, or inhibiting apoptosis of β-cells, comprising administering to a patient in need thereof an effective amount of a GLP-1 compound [whereto is attached] wherein a lipophilic substituent is optionally attached via a